Description
A kit of 10 vials of Semaglutide. Each vial contains 5mg of lyophilized Semaglutide.
Semaglutide is a GLP-1 receptor agonist available as a once-weekly injection and, in some indications, as a daily oral medication. It mimics the GLP-1 hormone, which increases glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on appetite-regulating pathways in the brain. The practical result is improved blood-sugar control, reduced appetite, and weight loss.
It has a large and mature evidence base across type 2 diabetes, obesity, and cardiovascular disease. In obesity trials, semaglutide 2.4 mg produced average weight losses in the range of roughly 15% over about 68 weeks, with substantial variation between individuals. In diabetes trials, it consistently lowers HbA1c and body weight.
Its evidence extends beyond weight loss. SUSTAIN-6 found fewer major cardiovascular events among high-risk patients with type 2 diabetes receiving semaglutide, and the much larger SELECT trial subsequently showed a cardiovascular benefit in people with overweight or obesity and established cardiovascular disease even without diabetes. More recent evidence also supports cardiovascular benefit with oral semaglutide in high-risk type 2 diabetes.





